课题基金 / 基金详情

COVID-19 Variant Supplement - Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease

COVID-19 Variant Supplement - Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
COVID-19 变异补充剂 - COVID-19 疾病后持续 SARS-CoV-2 抗体反应的早期免疫预测因子
批准号：
443129
负责人：
Kaufmann Daniel E
金额：
$3.64万
依托单位：
Centre hospitalier de l'Universit de Montral (CHUM)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-02-01 至 2022-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443129&lang=en
关键词：
Adaptive Immunity Antibody Responses Covid-19 Heath Care Workers Immune Predictors Of Disease Risk Innate Immunity Personalized Medicine Protective Antiviral Immune Responses Sars-Cov-2 Systems Biology

项目摘要

项目成果

Kaufmann Daniel E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
COVID-19, a disease caused by a new Coronavirus, is an unprecedented global health crisis for which we currently have nor safe nor rapid response. Given the absence of vaccines and effective therapies, it is essential to understand the development, effect
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunovirological determinants of breakthrough COVID-19 disease in vaccinated or previously infected individuals
Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
The molecular basis of persistent HIV-specific CD4 T cell dysfunction
Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens
海外基金